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Antibiotic resistance in clinically important bacteria can be medi-
ated by target protection mechanisms, whereby a protein binds to
the drug target and protects it from the inhibitory effects of the
antibiotic. The most prevalent source of clinical resistance to the
antibiotic fusidic acid (FA) is expression of the FusB family of
proteins that bind to the drug target (Elongation factor G [EF-G])
and promote dissociation of EF-G from FA-stalled ribosome com-
plexes. FusB binding causes changes in both the structure and con-
formational flexibility of EF-G, but which of these changes drives
FA resistance was not understood. We present here detailed char-
acterization of changes in the conformational flexibility of EF-G in
response to FusB binding and show that these changes are respon-
sible for conferring FA resistance. Binding of FusB to EF-G causes a
significant change in the dynamics of domain III of EF-GC3 that
leads to an increase in a minor, more disordered state of EF-G
domain III. This is sufficient to overcome the steric block of trans-
mission of conformational changes within EF-G by which FA pre-
vents release of EF-G from the ribosome. This study has identified
an antibiotic resistance mechanism mediated by allosteric effects
on the dynamics of the drug target.
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Antibiotic resistance is an emerging public health crisis thatthreatens our ability to treat bacterial infections (1). To
effectively tackle this problem, a comprehensive understanding of
the mechanisms of resistance to these important drugs is crucial,
especially because knowledge of these mechanisms in molecular
detail could lead to strategies to overcome them and prolong the
usefulness of current antibiotics. While many resistance mecha-
nisms are broadly understood, there remain some notable gaps,
particularly in our understanding of target protection mechanisms
of resistance. In such cases, a resistance protein binds to the drug
target, and through this protein–protein interaction protects the
target protein from inhibition by the drug. Examples of target
protection mechanisms that have been identified to date are the
FusB-like proteins (2, 3) and the quinolone resistance protein Qnr
(4), but an understanding of the mechanisms of resistance at the
molecular level is lacking in both cases. However, the recent
identification of ABC-F proteins as mediating resistance to a
range of clinically important antibiotics through target protection
(5) suggests that such mechanisms may be more clinically signifi-
cant than previously understood.
Fusidic acid (FA) is one of few remaining antibiotics that can
be administered orally to treat methicillin-resistant Staphylo-
coccus aureus infections and is also used topically to treat skin
and soft tissue infections, but resistance to this important anti-
biotic has risen significantly in recent years (6–8). The major
clinical source of FA resistance is heterologous expression of the
FusB family of proteins (8–11). While recent advances have
provided insight into FusB-mediated FA resistance (3, 12, 13),
questions remain regarding the underlying molecular mechanism
of resistance. Here we elucidate the key mechanisms that allow
FusB to confer FA resistance.
Elongation factor G (EF-G) is an essential translocase during
protein synthesis, responsible for promoting translocation of
transfer RNA (tRNA) from the A to the P site of the ribosome
following peptide bond formation (14, 15). EF-G must then be
released to allow further rounds of chain elongation to occur. FA
binds to EF-G when it is bound to the ribosome during the
translocation phase and prevents its release, stalling protein
synthesis (16). The FusB family of proteins confer FA resistance
by binding to EF-G and promoting dissociation of these stalled
complexes via a target protection mechanism to allow protein
synthesis to continue (2, 3, 12). We recently solved the solution
structure of FusB bound to EF-GC3 (domains III to V of EF-G),
showing that FusB binds to domain IV of EF-G and does not
interact with the FA-binding site between domains II and III
(12). Our structure showed conformational changes in both EF-
GC3 and FusB upon forming the complex and also identified
evidence of a change in the conformational flexibility of domain
III in response to FusB binding. However, it was not possible to
determine whether the FusB-induced structural changes or the
change in conformational flexibility was responsible for confer-
ring resistance to FA, leaving the key question of how FusB
causes FA resistance unanswered.
In this study we have used NMR relaxation dispersion to
characterize the differences in conformational flexibility in EF-
GC3 in the apo- and FusB-bound forms to determine the effect of
FusB binding on domain III of EF-G. By disrupting these dy-
namics, without perturbing FusB binding and the conformational
changes in domains IV and V, we were able to separate the
dynamic and structural effects of FusB binding on FA resistance
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to determine whether the conformational flexibility or changes in
the domain orientations within EF-G are the most significant
cause of FA resistance. Our data show that FusB binding in-
creases the population of a minor state of EF-GC3 with a more
disordered domain III. Preventing the formation of this in-
creased minor state population in response to FusB binding
prevents FusB from rescuing EF-G from FA-stalled ribosome
complexes, showing that this change in domain III dynamics is
key to FusB-mediated FA resistance.
Results
Binding to FusB Triggers a Change in Conformational Dynamics
throughout Domain III of EF-GC3. The 1H-15N amide NMR signals
throughout domain III of EF-GC3 broaden upon binding to FusB,
suggesting a change in the conformational flexibility of this do-
main upon FusB binding (12). It is remarkable that nearly all of
the amide signals from a single domain become undetectable in
the NMR spectrum. This may partly be a consequence of the
conditions (pH 8.0 and 30 °C) used for our NMR experiments. If a
state is involved with little or no protection from hydrogen ex-
change such as a partially or fully unfolded state, then the ex-
pectation would be that amide signals broaden beyond detection
through increased hydrogen exchange. Therefore, to determine
whether broadening of amide signals as a result of increased
amide exchange is an important factor at the higher pH at which
experiments are conducted, 1H-15N-TROSY-HSQC spectra were
recorded over the pH range 6.6 to 8.5 (SI Appendix, Fig. S7).
These spectra showed that only two additional resonances became
visible at pH 6.6, suggesting that the majority of domain III peaks
remain broadened at a lower pH. Due to the reduction in amide
exchange rate at lower pHs, this lack of additional resonances
suggests that the previously identified broadening of amide reso-
nances from domain III (12) is not only due to amide exchange,
but also likely reflects conformational exchange and that the
combination of both processes may be responsible for the almost
uniform disappearance of amide signals from domain III. Fortu-
nately, the majority of 13C-1H ILVA methyl resonances remain
visible in 1H-13C heteronuclear multiple quantum coherence
(HMQC) spectra, while some resonances from domain III (I408,
A426, A439, and L461) are also broadened beyond detection in these
spectra in the FusB-bound state but present in the apo spectra.
I450, while present in the HMQC spectrum, is also noticeably
broadened in the FusB-bound state. This further supports the
suggestion that conformational exchange causes considerable
broadening in both amide and methyl groups. The higher quality
and sensitivity of the methyl spectra allow this process to be more
closely investigated.
To understand how the dynamics of EF-GC3 domain III change
in response to FusB binding, we used 1H-13C ILVA methyl re-
laxation dispersion experiments (17) to compare dynamics within
EF-GC3 in the presence and absence of FusB. These relaxation
dispersion experiments are used to study residues that undergo
chemical exchange on a μs-ms timescale between two states for
which the NMR chemical shifts are different. Fitting of these data
allows extraction of quantitative parameters for the rate of ex-
change between states, the populations of the two states, and the
difference in chemical shift between them (|Δω|). This allows
identification of which residues are involved in exchange processes
and grouping of residues reporting on the same global exchange.
To study dynamics in EF-GC3, methyl-TROSY
1H-13C multiple
quantum Carr-Purcell-Meiboom-Gill (CPMG) relaxation disper-
sion was used (18), allowing identification of methyl groups in-
volved in exchange.
When bound to FusB, many residues within domain III of EF-
GC3 showed relaxation dispersion profiles (Fig. 1 and SI Ap-
pendix, Fig. S1) that indicate these residues are undergoing ex-
change on the μs-ms timescale (V412, A418, L427, V448, I449, I450,
I460, and A477). Several additional residues showed broadening
or signs of dispersion indicating that these residues also undergo
exchange, but the peaks became too broad to allow for accurate
fitting of R2
eff values or dispersion profiles (residues A426, A439,
L430, and L461). Relaxation dispersion data were fitted to a
standard two-state exchange model. Fitting of dispersion data for
each affected residue within domain III independently showed a
similar exchange rate and population of the minor state, sug-
gesting a global effect throughout the domain in response to
FusB binding. Therefore, fitting was repeated for all residues
within domain III using a global exchange rate and population to
reflect a single event. This identified an exchange process that
occurred at a rate of 930 ± 90 s−1 with a minor state population
of 4.7 ± 0.2%. Relaxation dispersion effects were also identified
within domains IV and V (residues I600, I609, I619, V678, and A683,
SI Appendix, Fig. S2).
In apo EF-GC3, dispersion profiles similar to those seen in the
presence of FusB were observed for residues I600, I609, I619, V678,
and A683 in domains IV and V (SI Appendix, Fig. S2). This
suggests that the dynamics seen for these residues in the FusB
bound state are not caused by FusB binding. Therefore, these
effects are not likely to influence FA resistance and are instead
likely to be related to the conformational flexibility of EF-G that
allows it to catalyze translocation of the ribosome. In contrast to
the FusB bound form, few of the residues in domain III undergo
dynamics on the μs-ms timescale in the apo state, and those that
do (residues I408, A418, I449, and I460) have significantly reduced
relaxation dispersion profiles compared to the FusB-bound state,
as shown by significantly reduced differences in R2
eff with
changes in CPMG field strength (Fig. 1). Global fitting of dis-
persion profiles for residues in domain III in the apo state
identified a similar exchange rate to the FusB-bound state
(1,100 ± 120 s−1) but a reduced population of the minor state of
0.59 ± 0.03%. This suggests that binding of FusB is causing a
change in the equilibrium of an exchange process that occurs
within EF-GC3, rather than creating a new exchange process,
increasing the population of a minor state that could have an
effect on the ability of FA to inhibit release of EF-G from
the ribosome.
To investigate the likely changes within domain III of EF-GC3
further, hydrogen exchange–mass spectrometry (HX-MS) was
used to compare the apo and FusB-bound states of EF-GC3.
These data showed that regions within domains IV and V show
the greatest protection from exchange in the presence of FusB
(Fig. 2 and SI Appendix, Fig. S3), confirming the role of these
regions in FusB binding. In contrast, domain III shows wide-
spread deprotection in response to FusB binding (i.e., residues
throughout this domain become more solvent exposed and less
hydrogen bonded). This occurs throughout the domain with the
greatest effects seen within the α-helices and two of the β-strands
(Fig. 2 and SI Appendix, Fig. S3). Most of the residues that show
conformational exchange in the FusB-bound state, as deter-
mined by relaxation dispersion (Fig. 2C), fall within the most
deprotected area of domain III or form interactions with resi-
dues in the deprotected regions. The widespread nature of the
deprotection within domain III suggests that it may be less or-
dered in the FusB-bound state. Such disorder within domain III
could promote FA resistance by preventing the steric block of
transmission of conformational changes from domains I and II to
domain III caused by FA binding to allow EF-G to take up the
conformation necessary for ribosome release.
In light of the HX-MS data suggesting disorder in domain III
in the minor state, we calculated amide exchange rates assuming
domain III became unfolded in the FusB-bound state using the
program SPHERE (https://protocol.fccc.edu/research/labs/roder/
sphere/sphere.html) (19, 20). This predicted an average exchange
rate of ∼160 s−1 at pH 8.0 and ∼5 s−1 at pH 6.6 for domain III
residues. This suggests that at pH 8.0 amide NMR resonances
from a disordered domain III are likely to be broadened while at






















pH 6.6 it is likely that some resonances would be visible. As amide
resonances are not visible at pH 6.6, this suggests that solvent
exchange in a disordered domain is not sufficient to explain the
loss of amide signals. However, while not completely responsible
for amide signal broadening, disorder in a minor state of domain
III likely contributes to the widespread broadening of domain III
resonances in addition to conformational exchange and could help
to explain why so many signals from this domain are lost in the
presence of FusB.
To determine whether the FusB-induced disordered domain
III minor state is the result of domain III becoming unfolded in
the presence of FusB, we compared the difference in chemical
shift between the major and minor states extracted from the
CPMG relaxation dispersion fitting (|Δω|, SI Appendix, Table S1)
with the difference between observed chemical shifts and refer-
ence values for unfolded proteins (secondary shifts) (21) (SI
Appendix, Fig. S4). While 1H |Δω| in the FusB-bound state cor-
related well with secondary shifts, the 13C |Δω|-to-secondary shift
correlation is weak with large differences for some residues, sug-
gesting that the minor state, while more disordered, does not
consist of a fully unfolded domain III. Instead, it is more likely that
domain III is becoming more flexible and potentially losing some
secondary structure order without resembling a random coil.
Changes in the Dynamics of Domain III Are Key to FA Resistance. Our
previous structural model of the FusB:EF-GC3 complex identified
both a change in the dynamics of domain III and also structural
changes in domains IV and V in response to FusB binding (12),
preventing an analysis of whether the changes in conformational
flexibility are important in the mechanism of FA resistance. To
determine whether the FusB-induced dynamics changes within
domain III or the domain IV and V conformational changes are
most important for FA resistance, mutations were introduced into
domain III of EF-GC3 to disrupt the effects of FusB binding on
domain III dynamics without disrupting the conformational
changes in domains IV and V upon FusB binding. These muta-
tions were H438P to restrain the movements of a flexible loop,
H409K/M479E double mutant to introduce a salt bridge between
β-strands within domain III, N470D to introduce a salt bridge be-
tween the end of an α-helix and a β-strand, and H438C/G451C
double mutant to create a disulfide bond between β-strands that
both show FusB-induced deprotection within domain III (SI Ap-
pendix, Fig. S5). For each of the 4 EF-GC3 variants, amide
1H-15N
HSQC-TROSY and 1H-13C methyl HMQC spectra in the FusB-
bound state overlaid well with the wild-type FusB-bound spectra
with no evidence of apo EF-GC3 peaks. This showed that the
mutations did not prevent FusB binding or the conformational
changes that occur upon FusB binding (SI Appendix, Fig. S5).
Analysis of amide chemical shift differences between wild-type
and mutant proteins for EF-GC3 H438C/G451C, and EF-GC3
H438P (SI Appendix, Fig. S5) showed that chemical shift differ-
ences were small with a maximum of 0.26 ppm and were similar
throughout the protein, suggesting that they are limited to ex-
perimental variation, with the exception of G446, G556, S586, and
N661 in EF-GC3 H438P. However, G446 (the largest chemical shift
difference) is close to the site of the introduced mutation and
Fig. 1. Comparison of relaxation dispersion effects in domain III of EF-GC3 in the presence and absence of FusB. (A) Methyl relaxation dispersion curves
measured for residues in domain III in EF-GC3:FusB at 950 MHz (magenta) and 750 MHz (blue) and in apo EF-GC3 at 950 MHz (orange) and 750 MHz (green),
showing significant dispersion effects in the complex that are absent or greatly reduced in the unbound protein, as shown by a reduced difference in R2
eff
over the range of νCPMG field strengths. (B and C) Mapping of residues showing relaxation dispersion effects on the structure of domain III of EF-G in the apo
state [Protein Data Bank (PDB) ID: 2XEX (24)] in the absence (B) and the presence (C) of FusB. Residues showing dispersion effects in each case are colored by
the magnitude of the difference in chemical shift (blue: <0.2 ppm; light blue: 0.2 to 0.4 ppm; cyan: 0.4 to 0.6 ppm; green: 0.6 to 0.8 ppm; orange: >0.8 ppm;
red: broadens and cannot be accurately fitted; dark gray: unassigned). Dispersion effects are spread more widely throughout domain III and involve more
residues in the presence of FusB. All relaxation dispersion data were acquired at 30 °C with a relaxation delay of 24 ms. No structure of domain III in the
complex state is currently available as NMR signal broadening prevented modeling of this domain in the complex structure (12). Errors in R2
eff were de-
termined through repeated measurement of two data points per experiment. Where error bars are not visible, they are within the limits of the data point. For
each relaxation dispersion experiment, n = 13 at each field.













































could reflect localized changes resulting from the introduced
mutation while the remaining residues are spread throughout the
protein. For 1H-15N TROSY-HSQC spectra of EF-GC3 H438C/
G451C bound to FusB, in addition to the expected FusB-bound
peaks, some additional peaks appear (SI Appendix, Fig. S5D).
These resonances could be from residues within domain III that
are broadened in response to FusB binding causing exchange on
the μs-ms timescale (12) and could therefore suggest that the
H438C/G451C mutation stabilizes the domain, disrupting the
change in the dynamics of domain III induced by FusB binding,
preventing broadening of these resonances.
ILVA methyl relaxation dispersion experiments were per-
formed for each of these four variants in the FusB-bound state at
950 MHz to determine if the mutations caused any changes in
the dynamics of the protein. As these data were acquired only at
a single magnetic field strength, it is not possible to extract ac-
curate parameters from fitting these data as discussed for the
wild-type data at two field strengths. However, such data can be
used for qualitative comparison to determine whether dynamics
effects are different from those in the wild-type protein to
identify those mutations that disrupt effects observed in the wild-
type protein. For EF-GC3 H409K/M479E, residues showing dis-
persion profiles in the wild-type complex showed similar effects
in the mutant complex, suggesting that this mutation did not
affect the ability of FusB to induce changes in the dynamics of
domain III (Fig. 3). Likewise, the N470D mutation showed little
change in the dynamics of EF-GC3 compared with the wild-type
protein. This suggests that the exchange process induced by FusB
may not involve significant disruption of these interactions. In
support of this, the H409K/M479E expected additional salt bridge
involves a β-strand on the edge of domain III that shows the
lowest levels of HX-MS deprotection in response to FusB
binding, and this region of the protein may be less affected by
FusB binding.
For both EF-GC3 H438P and EF-GC3 H438C/G451C, ILVA
methyl relaxation dispersion experiments in the presence of
FusB showed marked differences from the wild-type complex.
For both mutations, the residues in domain III that show large
dispersion profiles in the wild-type complex showed no or sig-
nificantly reduced dispersion profiles in the presence of FusB,
suggesting that these mutations did indeed allow the dynamics in
domain III to be restrained in the presence of FusB (Fig. 3).
Comparison of relaxation dispersion curves for residues in do-
mains IV and V showed that residues within these domains in
the EF-GC3 H438C/G451C mutant gave similar dispersion to those
of the wild type protein, suggesting the exchange that occurs in
both apo- and FusB-bound states remains unchanged for this
mutant (SI Appendix, Fig. S6). Although there is some suggestion
of reduced dispersion curves in the EF-GC3 H438P mutant, the
same residues show dispersion as those seen for wild-type EF-
GC3, and it is possible that the differences could reflect changes
that also occur in the apo state for this mutant. The fact that
there are no significant differences between the FusB-bound
NMR spectra for these proteins compared to the wild type
shows that both mutations allow the separation of the confor-
mational change upon FusB binding from the change in the
dynamics of domain III, allowing these mutants to be used to
determine which process is most important in conferring FA
resistance.
As both mutations resulting in changes in the dynamics of EF-
GC3 domain III upon FusB binding involve substitution of a
histidine, 1H-13C HMQC and 1H-15N-TROSY-HSQC spectra of
ILVA-labeled EF-GC3 bound to FusB were measured over a pH
range of 6.6 to 8.5 to ensure that the relaxation dispersion pro-
files observed in the wild-type protein were not the result of
histidine protonation/deprotonation. The HMQC spectra
showed very little change in chemical shift with pH (SI Appendix,
Fig. S7) over this range, suggesting that there is little effect of
histidine titrations on the chemical shifts of these residues. The
greatest effect of pH on chemical shift within domain III is for
A477, which has changes in
1H and 13C chemical shifts of 0.084
and 0.138 ppm, respectively, suggesting that the titration of a
sidechain in the region has an effect. However, plotting the
chemical shift against pH suggests that this is responding to
something with a pKa greater than 8.5 and so is unlikely to be the
result of a histidine. Also, this effect is localized to A477, which is
Fig. 2. Comparison of hydrogen exchange mass spectrometry data in EF-GC3 in the apo- and FusB-bound states. (A) Regions of EF-GC3 that are protected
(blue) or deprotected (red) from exchange in the presence of FusB are shown in the structure of the FusB:EF-GC3 complex (12) (PDB ID: 2MZW). The structure
of domain III is modeled on the basis of the EF-G apo structure (24) (PDB ID: 2XEX) as no structure of this domain in the FusB-bound complex is available (12).
Domains IV and V are protected from exchange upon FusB binding, particularly in the regions that contact FusB, while domain III becomes deprotected
throughout the domain. FusB is shown in green. (B and C) Comparison of regions within domain III showing HX-MS deprotection. SI Appendix, Fig. S3 (B and
C) Comparison of regions within domain III showing HX-MS deprotection (B) with residues showing relaxation dispersion effects upon FusB binding (C). (B)
Dark red indicates greater levels of deprotection, as shown in SI Appendix, Fig. S3. (C) Residues colored red undergo dispersion in CPMG experiments in EF-
GC3 bound to FusB. Both significant deprotection and relaxation dispersion occur in the center of the domain, suggesting that they reflect the same change.
Data in B and C are shown on the structure of apo EF-G (24) (PDB ID: 2XEX) as no structure of this domain in the presence of FusB is available (12).






















not close to the mutated H438, and it is unlikely that titration of
this histidine could affect A477 but not residues closer to it.
Furthermore, for the change in dynamics within domain III to be
reflecting histidine titrations, the chemical shift changes would
be expected to be much more widespread to resemble the extent
of changes in relaxation dispersion. Therefore, it is unlikely that
the change in relaxation dispersion data in the H438P and H438C/
G451C mutants compared to the dispersion profiles observed in
the wild-type protein reflects responses to histidine protonation/
deprotonation. These results therefore reflect real changes in the
interactions within domain III in response to FusB binding.
To assess the role of these mutations in FA resistance, a
fluorescence-based assay to follow the buildup of stalled ribo-
some:EF-G:GDP complexes was employed (3). Escherichia coli
ribosomes were mixed with EF-G and fluorescent BODI-
PY-FL-GDP, and increasing concentrations of FA were added.
The formation of the ribosome:EF-G:GDP complex results in a
large increase in the fluorescence of BODIPY-FL-GDP, and
Fig. 3. Comparison of the effects of mutations in EF-GC3 methyl relaxation dispersion. Comparison of methyl relaxation dispersion data for wild-type (cyan)
and mutant (magenta) forms of EF-GC3 bound to FusB for (A and B) EF-GC3 H438P, (C and D) EF-GC3 H438C/G451C, (E and F) EF-GC3 H409K/M479E, and (G and H) EF-
GC3 N470D showing EF-GC3 H409K/M479E and N470D have relaxation dispersion curves for residues in domain III that are similar to those in the wild-type protein
while the remaining variants show little or no relaxation dispersion for these residues. Data were acquired at 950 MHz, 30 °C, with a relaxation delay of 24 ms.
Errors in R2
eff were determined through repeated measurement of two data points per experiment. For each experiment, n = 13.













































therefore the effect of increasing concentrations of FA in forming
stalled complexes can be measured. Adding FusB in a 1:5 EF-
G:FusB molar excess allows the determination of whether FusB
can prevent the buildup of these stalled complexes. To ensure that
the mutations in EF-G do not prevent ribosome binding or cause
FA resistance, this assay was first performed in the absence of
FusB. For EF-G H409K/M479E, H438P and H438C/G451C, similar
fluorescence curves to those observed for wild-type EF-G were
produced, showing that the proteins bind to the ribosome and can
be inhibited by FA (Fig. 4). In order to produce the same mag-
nitude of fluorescence change as the wild type, the concentration
of EF-G H438P needed to be increased, suggesting that this mu-
tation did reduce the overall affinity of EF-G for the ribosome.
However, this was subsequently compensated for by an increased
concentration of FusB to maintain the 1:5 molar ratio. For EF-G
H438C/G451C, while a curve similar to that obtained with wild-type
EF-G was produced, the total fluorescence change was slightly
reduced after increasing the EF-G concentration compared to
wild type, suggesting that this mutation also reduces the affinity of
EF-G for the ribosome. However, the effects of FusB binding can
still be assessed based on differences for this mutant in the pres-
ence and absence of FusB in the same 1:5 molar ratio.
In the presence of FusB, very little fluorescence change was
observed for either the wild-type or EF-G H409K/M479E proteins
(Fig. 4), showing that both can be prevented from forming the
stalled complexes by FusB. However, for both EF-G H438P and
EF-G H438C/G451C, there was a marked increase in fluorescence
in response to increasing concentrations of FA even in the
presence of FusB. This shows that both mutations impair the
ability of FusB to rescue EF-G from forming stalled complexes.
For EF-G H438C/G451C, the response in the presence of FusB is
clearly different from the wild-type protein, but due to larger
error bars, the response of EF-G H438P to FA in the presence of
FusB cannot confidently be said to be significantly different from
the wild-type protein. The increased fluorescence response,
however, does suggest that the protein is more susceptible to FA
than the wild type. For EF-G H438C/G451C, the response to FA
addition in the presence of FusB closely resembled that in the
absence of FusB, while in the case of EF-G H438P the profile of
the curve was similar to that of the protein in the absence of
FusB, but the maximum change in fluorescence was less. This
shows that, while both mutations impair FusB-mediated FA re-
sistance, the H438P mutation does not abolish it completely as
the magnitude of the fluorescence increase does not return to
levels seen in the absence of FusB. However, these effects show
that the change in the dynamics of domain III in response to
FusB binding are important in the mechanism of FusB-mediated
FA resistance as the conformational change within domains IV
and V is not sufficient to confer FA resistance. It is likely that the
H438P mutation has impaired rather than abolished the changes
within domain III, accounting for the inability of the mutation to
completely abolish FA resistance.
Discussion
The FusB family of proteins comprises the major source of clinical
resistance to FA (10), but, despite recent progress, questions re-
main over the molecular mechanism of resistance. Our previous
work has shown that FusB binding causes both conformational
changes in EF-GC3 and allosterically induced changes in the
conformational flexibility of domain III (12). However, the rela-
tive importance of the conformational and dynamics changes in
response to FusB binding and the nature of the changes in domain
III dynamics could not be determined. In this work, we have
characterized these changes in dynamics and determined their
relative importance in the mechanism of resistance to FA.
Comparing relaxation dispersion data in the apo- and FusB-
bound forms of EF-GC3, it is clear that there is a widespread
change in the dispersion profiles within domain III in response to
Fig. 4. The impact of FusB upon accumulation of stalled ribosome:EF-G:GDP:FA complexes. Fluorescence of BODIPY-FL-GDP in response to increasing con-
centrations of FA in the absence (closed circles) and presence (open circles) of FusB for (A) wild-type EF-G, (B) EF-G H409K/M479E, (C) EF-G H438P, and (D) EF-G
H438C/G451C. Data show that, for both wild-type and EF-G H409K/M479E, stalled complexes accumulate in the absence of FusB but little accumulation is ob-
served in the presence of FusB, as FusB promotes dissociation of these complexes. In contrast, for both EF-G H438P and EF-G H438C/G451C, stalled complexes
build up in the absence of FusB, similar to the wild-type protein, but both mutant proteins show an increase in fluorescence with increasing FA concentration
in the presence of FusB. The large error bars for EF-G H438P mean that a significant difference from wild type cannot be shown with certainty, but the data
suggest increased formation of stalled complexes in the presence of FusB. While not restored to levels in the absence of FusB for EF-G H438P, these data show
that the H438P and H438C/G451C mutations at least partially restore FA sensitivity in the presence of FusB. This suggests that the changes in dynamics in re-
sponse to FusB binding that are suppressed by these mutations are important in the mechanism of FusB-induced FA resistance. Each data point represents the
mean value after three independent repeats with error bars representing the SD from the mean. For each experiment, n = 15.






















FusB binding. However, fitting the smaller dispersion profiles in
the apo state suggests that FusB likely significantly increases the
population of a minor state that occurs in apo EF-GC3, rather
than instigating an exchange process that does not occur in the
absence of FusB. The widespread deprotection observed by HX-
MS, extending throughout both helices and the β-sheet, suggests
that this minor state is likely to be a more disordered form of
domain III, similar to the partially disordered nature of domain
III in some crystal structures of EF-G (22, 23), rather than a
defined minor state conformation, as reduction of amide hy-
drogen bonding within all secondary structure elements suggests
destabilization of all of the structure of the domain. Differences
in chemical shifts between major and minor states suggest that
the minor state includes a more disordered, but not a fully un-
folded, domain III. This agrees with the widespread resonance
broadening in the NMR spectra and conformational exchange ob-
served by relaxation dispersion, as a single conformational change
would not be expected to cause effects throughout the domain.
EF-G undergoes several conformational changes throughout
translocation that are central to its function. Comparison of
structures of EF-G determined in the apo form (24, 25),
nucleotide-bound form (23, 26), and resident on the ribosome
pre- and post translocation (27–29) show that major structural
rearrangements occur within EF-G throughout the translocation
cycle, most of which involve domains I and II moving relative to
domains III to V (30). Dissociation of EF-G from the ribosome
following translocation requires conformational changes to be
transmitted from domains I and II to domain IV to disrupt the
contacts that this domain makes with the 30S subunit of the ri-
bosome (29). FA inhibits dissociation of EF-G from the ribosome
by binding to EF-G between domains II and III and apparently
restricting this transmission of conformational change (27).
The increased population of a more disordered minor state
observed in this study would cause EF-G, on average, to take up
this minor state more often, and it is likely that this state is
sufficient to allow release from the ribosome by preventing the
steric block of conformational change in domains III to V con-
ferred by FA (27). This increase in population could therefore be
enough to allow release of EF-G from the stalled complexes to
allow protein synthesis to continue. FusB-mediated resistance
has been shown to confer FA resistance to around 16 μg/mL FA
(31), a lower concentration than that which can be conferred by
some mutations within EF-G itself (fusA-type resistance) [e.g.,
L461K > 256 μg/mL (32) for a mutation within the FA-binding
site that is likely to reduce FA affinity]. If FusB acts to increase
the population of a more disordered “ribosome-release” con-
formation of EF-G, then this would most likely have an upper
limit to its ability to confer resistance. Too great an increase in
the population of this state would itself inhibit protein synthesis
by destabilizing the EF-G:ribosome binding interaction to the
extent that EF-G could not function effectively in translocation,
and the fact that the more disordered state remains a minor state
would reflect that. This may well explain why resistance levels are
more modest for FusB-type resistance than for mutations in EF-
G expected to directly reduce the affinity for FA.
The increased buildup of FA-stalled complexes in the pres-
ence of FusB for those mutant EF-G proteins that do not allow
FusB to confer the same change in the population of the minor
state suggests that it is this change in the equilibrium between the
native and the more disordered states of domain III, and not the
conformational change in domains IV and V upon binding (12),
that allows FusB to confer FA resistance. This model for the
FusB-mediated resistance mechanism is consistent with previ-
ously published data that show that FusB can act as a release
factor, increasing release of EF-G from the ribosome in the
absence of FA (3) as increasing a more disordered ribosome-
release state would necessarily cause increased dissociation of
EF-G from the ribosome regardless of whether FA is present.
The Kd of EF-G for FusB is in the nanomolar range (3), and EF-
G binds to FusB in the absence of the ribosome so it is likely that
a significant proportion of EF-G in the cell would be bound to
FusB, thereby increasing release from the ribosome.
In light of these findings, we therefore propose that FusB-
mediated FA resistance occurs through an allosterically in-
duced change in the conformational flexibility of domain III of
EF-G in response to FusB binding (Fig. 5). This increases the
population of a more disordered state of domain III. During
translocation, conformational changes within domain III are
thought to cause movement of domains IV and V relative to
domains I and II in response to conformational changes in the
latter domains upon GTP hydrolysis (30). FA has been shown to
prevent these changes by mimicking the GTP-bound state of
domains I and II where they contact domain III (27). If FusB
binding causes domain III to become more flexible, then this
would allow movement of domains IV and V relative to domains
I and II irrespective of conformational changes in these domains
and so allow release of EF-G from the ribosome. In the presence
of FA, this could well be enough to allow transient formation of
Fig. 5. The proposed mechanism of FusB-mediated FA resistance. In the absence of FA, EF-G (blue) binds to the ribosome (brown) and catalyzes translocation
of the tRNA (green) from the A (acceptor) and P (peptidyl) to the P and E (exit) sites. GTP hydrolysis causes EF-G to undergo a conformational change (light
blue), allowing EF-G to dissociate from the ribosome. In the presence of FA, FA (red) binds to EF-G following GTP hydrolysis and prevents the conformational
change so that EF-G does not dissociate from the ribosome. FusB (yellow) binding to EF-G promotes an increased population of a minor state of EF-G with a
more disordered domain III, allowing EF-G to undergo the conformational change required for release from the ribosome even while bound to FA.













































the GDP-bound conformation and cause release of EF-G from
the ribosome even in the presence of the inhibitory drug and
therefore allow protein synthesis to continue. In the absence of
FA, this same effect would lead to greater release of EF-G from
the ribosome. Once released from the ribosome, EF-G has a
much-reduced affinity for FA (14) so the drug would be expected
to dissociate from EF-G, allowing protein synthesis to continue.
This mechanism of FA resistance is consistent with all available
data and previously published results (3, 12). As a small pop-
ulation of the minor state is present in the absence of FusB, this
opens up the intriguing possibility that disorder in domain III
plays a role in the normal release of EF-G from the ribosome
where FusB is absent. However, further investigation will be
needed to establish if this is the case.
Allosteric effects have been shown to play a significant role in
only two resistance mechanisms to date: FusB-mediated FA re-
sistance (12) and PBP2a-mediated methicillin resistance (33, 34),
while a mechanism that requires changes in the dynamics of the
drug target has not previously been reported to the best of our
knowledge. However, given the importance of dynamics in the
correct functioning of many proteins, it is likely that the mech-
anism outlined here represents a type of resistance mechanism
that plays a role in resistance to other antibiotics.
Materials and Methods
Additional details are available in SI Appendix, Supplementary Materials
and Methods.
Protein Overexpression and Purification. FusB, EF-G, and EF-GC3 were
expressed and purified as previously described (12). FusB and EF-G were
produced with no specific labeling while EF-GC3 was produced with either no
specific labeling, uniform 15N, 13C, and partial 2H labeling or ILVA methyl 13C
1H labeling on a uniformly 12C 2H 15N background as detailed in SI Appendix,
Supplementary Materials and Methods.
NMR. All NMR spectra were acquired using 200- to 250-μM protein samples in
20 mM Tris-HCl, 300 mM sodium chloride, 1 mM dithiothreitol (DTT), pH 8.0,
except for samples containing the H438C/G451C mutations for which the DTT
was omitted to allow for disulfide bond formation. Spectra were recorded
on Bruker Avance spectrometers at field strengths of either 950 or 750 MHz,
equipped with cryoprobes (TXO 5- mm probe or 3-mm TCI probe at 950 MHz
and TCI 5-mm probe at 750 MHz). Spectra for pH titrations were acquired
using 100 μM of protein on a Bruker Avance 600-MHz spectrometer equip-
ped with a 5-mm QCI-P cryoprobe. For samples in the FusB-bound state, the
protein under study was saturated with 1.5× nonisotopically enriched binding
partner. Where appropriate, all experiments were performed using TROSY
modifications (35) and deuterium decoupling. Data were processed in
NMRPipe (36) before assignment and measurement of chemical shift pertur-
bations by CCPN analysis (37). Peak intensity measurements were made using
NMRView (38). Some data analysis was performed using NMRbox (39).
NMR Resonance Assignment. ILVA methyl resonances for EF-GC3 in both the
apo and complex states were assigned using CCH-TOCSY spectra measured
at 750 MHz with reference to previously published backbone assignments
(12). These assignments were supplemented with HMQC spectra of EF-GC3
harboring conservative mutations to remove selected Leu, Val, or Ala resi-
dues to identify residues that could not be otherwise assigned. Each of these
samples contained one Ala-to-Gly, one Val-to-Ile, and one Leu-to-Ile muta-
tion to allow assignments to be made based on loss of peaks from the
methyl HMQC spectrum.
NMR–CPMG Relaxation Dispersion. NMR methyl relaxation dispersion exper-
iments were acquired at 30 °C at field strengths of both 950 and 750 MHz
using EFGC3 with
1H-13C labeled Ile Cδ, Leu Cδ, Val Cγ, and Ala Cβ on a 2H-12C
background in complex with unlabeled FusB. Experiments were conducted
using the pulse program of Korzhnev et al. (18) with a T2 mixing time of
24 ms and CPMG field strengths of 41.8. 83.8 (repeated), 126.1, 168.6, 210.4,
251.9, 335.4 (repeated), 502.0, 668.7, 835.4, and 1002.0 Hz. Errors in peak
intensities were estimated through the use of repeated CPMG field
strengths. Methyl groups showing relaxation dispersion were identified as
those with a difference in R2
eff over the course of the νCPMG field range of at
least 1 s−1. Methyl groups with overlapped peaks or those for which the
systematic variation in R2
eff was not less than the overall R2
eff change were
discounted. Methyl groups showing relaxation dispersion but for which peak
height was reduced to the noise level for some data points were noted as
showing dispersion but were not subsequently used for fitting as no accu-
rate R2
eff values could be obtained for those data points. Relaxation dis-
persion data were fitted to a standard two-state exchange model using
CATIA (40), initially fitting data for each residue separately and then
grouping data for residues showing similar kex and Pb values. A global fit to
a single kex and Pb was then performed. For samples containing mutations to
disrupt dynamics in EF-GC3, relaxation dispersion data were acquired at 950
MHz only.
Hydrogen Exchange–Mass Spectrometry. HX-MS experiments were performed
as previously outlined (41). Briefly, experiments were carried out using a HX
robot (LEAP Technologies) interfaced to an Acquity HX manager and M-Class
LC (Waters). Samples were prepared with either 8 μM of EF-GC3 or 8 μM of
EF-GC3 and 10 μM FusB in 10 mM potassium phosphate buffer, pH 8.0 con-
taining 300 mM NaCl. Thirty microliters of sample and 135 μL of deuterated
buffer (10 mM potassium phosphate buffer, pH 8.0, 300 mM NaCl, 82% D2O)
were mixed and incubated for 0.5, 2, 10, 30, or 60 min at 4 °C. For each
condition and time point, measurements were performed in triplicate. The
HX reaction was quenched by mixing 50 μL of the reaction with 100 μL of
quench buffer (10 mM potassium phosphate, 2 M Gdn-HCl, pH 2.2). Fifty
microliters of this sample was then injected into immobilized pepsin/asper-
gillopepsin columns (Affipro) (20 °C). A VanGuard Precolumn [Acquity UPLC
BEH C18 (1.7 μm, 2.1 mm × 5 mm, Waters)] was used to trap peptides for
3 min, after which they were injected into a C18 column (75 μm × 150 mm,
Waters). A 7-min gradient of 0 to 40% (vol/vol) acetonitrile (0.1% vol/vol
formic acid) in H2O (0.3% vol/vol formic acid) at 40 μL • min−1 was used to
separate the peptides. Separated peptides were infused into a Synapt G2Si
mass spectrometer (Waters) operating in HDMSE mode. Peptides were sep-
arated by ion mobility before being subjected to fragmentation by CID (col-
lision induced dissociation) (42). PLGS (v3.0.2) and DynamX (v3.0.0) (Waters)
were used for data analysis. Peptides were filtered in DynamX using the fol-
lowing parameters: minimum intensity = 1,000; minimum products per amino
acid = 0.3; maximum sequence length = 25; maximum parts-per-million error =
5; file threshold = 3. Deuterium uptake data for all time points are shown in SI
Appendix, Table S2. Deuteros (43) was used to determine if increases/decreases
in deuterium uptake between states were statistically significant and to visu-
alize the data. The raw data have been made available in the Proteo-
meXchange Consortium via the PRIDE (44) partner repository with the dataset
identifier PXD017491. A reporting summary (45) can be found in SI Appendix,
Table S4.
FA Inhibition Assay. To determine the effect of different mutations on the
sensitivity of EF-G to FA and the ability of FusB to rescue EF-G from stalled
complexes in the presence of FA, a fluorescence-based assay to measure the
buildup of stalled complexes was used (3). All experiments were performed
in triplicate. FA in the range 0 to 500 μM was added to a 50-μL solution
containing 0.5 μM E. coli ribosomes (NEB), 0.05 μM BODIPY-FL-GDP (Invi-
trogen), and either 0.5 μM EF-G, 0.8 μM EF-G H409K/M479E, 2.5 μM EF-G H438P,
or 5.0 μM EF-G H438C/G451C in 50 mM Tris–HCl, 70 mM NH4Cl, 30 mM KCl,
7 mM MgCl2, pH 7.5, in the presence and absence of FusB in a 5× molar
excess with respect to EF-G. Fluorescence was measured with an excitation
wavelength of 485 nm and an emission wavelength of 520 nm at 37 °C using
a FLUOStar Omega plate reader.
Data Availability. Assigned methyl chemical shifts for EF-GC3 in the apo- and
FusB-bound states have been deposited in the Biological Magnetic Resonance
Data Bank with the accession codes 50221 (46) and 50220 (47), respectively.
HX-MS data have been deposited in the ProteomeXchange Consortium with
the accession number PXD017491 (48). FA inhibition assay data are available in
the Open Science Forum (OSF) (https://osf.io/uq4g7) (49). Raw relaxation dis-
persion data are available in the OSF (https://osf.io/95v4r/) (50). All other data
are contained within the main text and SI Appendix.
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